448 related articles for article (PubMed ID: 33205006)
21. Therapeutic potential of targeting ceramide/glucosylceramide pathway in cancer.
Kartal Yandım M; Apohan E; Baran Y
Cancer Chemother Pharmacol; 2013 Jan; 71(1):13-20. PubMed ID: 23073611
[TBL] [Abstract][Full Text] [Related]
22. Mutant p53 increases exosome-mediated transfer of miR-21-3p and miR-769-3p to promote pulmonary metastasis.
Ju Q; Zhao L; Gao J; Zhou L; Xu Y; Sun Y; Zhao X
Chin J Cancer Res; 2019 Jun; 31(3):533-546. PubMed ID: 31354222
[TBL] [Abstract][Full Text] [Related]
23. Ceramide modulates pre-mRNA splicing to restore the expression of wild-type tumor suppressor p53 in deletion-mutant cancer cells.
Patwardhan GA; Hosain SB; Liu DX; Khiste SK; Zhao Y; Bielawski J; Jazwinski SM; Liu YY
Biochim Biophys Acta; 2014 Nov; 1841(11):1571-80. PubMed ID: 25195822
[TBL] [Abstract][Full Text] [Related]
24. Glucosylceramide synthase inhibitors differentially affect expression of glycosphingolipids.
Alam S; Fedier A; Kohler RS; Jacob F
Glycobiology; 2015 Apr; 25(4):351-6. PubMed ID: 25715344
[TBL] [Abstract][Full Text] [Related]
25. p53-R273H gains new function in induction of drug resistance through down-regulation of procaspase-3.
Wong RP; Tsang WP; Chau PY; Co NN; Tsang TY; Kwok TT
Mol Cancer Ther; 2007 Mar; 6(3):1054-61. PubMed ID: 17363498
[TBL] [Abstract][Full Text] [Related]
26. Cholesterol masks membrane glycosphingolipid tumor-associated antigens to reduce their immunodetection in human cancer biopsies.
Novak A; Binnington B; Ngan B; Chadwick K; Fleshner N; Lingwood CA
Glycobiology; 2013 Nov; 23(11):1230-9. PubMed ID: 23906628
[TBL] [Abstract][Full Text] [Related]
27. Mutant p53 elicits context-dependent pro-tumorigenic phenotypes.
McCann JJ; Vasilevskaya IA; McNair C; Gallagher P; Neupane NP; de Leeuw R; Shafi AA; Dylgjeri E; Mandigo AC; Schiewer MJ; Knudsen KE
Oncogene; 2022 Jan; 41(3):444-458. PubMed ID: 34773073
[TBL] [Abstract][Full Text] [Related]
28. ATP-binding cassette transporters mediate differential biosynthesis of glycosphingolipid species.
Budani M; Auray-Blais C; Lingwood C
J Lipid Res; 2021; 62():100128. PubMed ID: 34597626
[TBL] [Abstract][Full Text] [Related]
29. Incorporation of Fluorescence Ceramide-Based HPLC Assay for Rapidly and Efficiently Assessing Glucosylceramide Synthase In Vivo.
Khiste SK; Hosain SB; Dong Y; Uddin MB; Roy KR; Hill RA; Liu Z; Liu YY
Sci Rep; 2017 Jun; 7(1):2976. PubMed ID: 28592871
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of glycosphingolipid biosynthesis reverts multidrug resistance by differentially modulating ABC transporters in chronic myeloid leukemias.
Salustiano EJ; da Costa KM; Freire-de-Lima L; Mendonça-Previato L; Previato JO
J Biol Chem; 2020 May; 295(19):6457-6471. PubMed ID: 32229586
[TBL] [Abstract][Full Text] [Related]
31. Agents that reverse multidrug resistance, tamoxifen, verapamil, and cyclosporin A, block glycosphingolipid metabolism by inhibiting ceramide glycosylation in human cancer cells.
Lavie Y; Cao Ht; Volner A; Lucci A; Han TY; Geffen V; Giuliano AE; Cabot MC
J Biol Chem; 1997 Jan; 272(3):1682-7. PubMed ID: 8999846
[TBL] [Abstract][Full Text] [Related]
32. The chemosensitizing activity of inhibitors of glucosylceramide synthase is mediated primarily through modulation of P-gp function.
Chai L; McLaren RP; Byrne A; Chuang WL; Huang Y; Dufault MR; Pacheco J; Madhiwalla S; Zhang X; Zhang M; Teicher BA; Carter K; Cheng SH; Leonard JP; Xiang Y; Vasconcelles M; Goldberg MA; Copeland DP; Klinger KW; Lillie J; Madden SL; Jiang YA
Int J Oncol; 2011 Mar; 38(3):701-11. PubMed ID: 21186402
[TBL] [Abstract][Full Text] [Related]
33. p53-R273H promotes cancer cell migration via upregulation of neuraminidase-1.
Lv T; Lv H; Fei J; Xie Y; Lian D; Hu J; Tang L; Shi X; Wang J; Zhang S; Li F; Jiang X; Yi Y
J Cancer; 2020; 11(23):6874-6882. PubMed ID: 33123278
[TBL] [Abstract][Full Text] [Related]
34. Mutant TP53 interacts with BCAR1 to contribute to cancer cell invasion.
Guo AK; Itahana Y; Seshachalam VP; Chow HY; Ghosh S; Itahana K
Br J Cancer; 2021 Jan; 124(1):299-312. PubMed ID: 33144694
[TBL] [Abstract][Full Text] [Related]
35. Mutant p53 disrupts MCF-10A cell polarity in three-dimensional culture via epithelial-to-mesenchymal transitions.
Zhang Y; Yan W; Chen X
J Biol Chem; 2011 May; 286(18):16218-28. PubMed ID: 21454711
[TBL] [Abstract][Full Text] [Related]
36. Expression of glucosylceramide synthase, converting ceramide to glucosylceramide, confers adriamycin resistance in human breast cancer cells.
Liu YY; Han TY; Giuliano AE; Cabot MC
J Biol Chem; 1999 Jan; 274(2):1140-6. PubMed ID: 9873062
[TBL] [Abstract][Full Text] [Related]
37. A role for ceramide in driving cancer cell resistance to doxorubicin.
Liu YY; Yu JY; Yin D; Patwardhan GA; Gupta V; Hirabayashi Y; Holleran WM; Giuliano AE; Jazwinski SM; Gouaze-Andersson V; Consoli DP; Cabot MC
FASEB J; 2008 Jul; 22(7):2541-51. PubMed ID: 18245173
[TBL] [Abstract][Full Text] [Related]
38. Ceramide-Rubusoside Nanomicelles, a Potential Therapeutic Approach to Target Cancers Carrying p53 Missense Mutations.
Khiste SK; Liu Z; Roy KR; Uddin MB; Hosain SB; Gu X; Nazzal S; Hill RA; Liu YY
Mol Cancer Ther; 2020 Feb; 19(2):564-574. PubMed ID: 31645443
[TBL] [Abstract][Full Text] [Related]
39. Gemcitabine treatment induces endoplasmic reticular (ER) stress and subsequently upregulates urokinase plasminogen activator (uPA) to block mitochondrial-dependent apoptosis in Panc-1 cancer stem-like cells (CSCs).
Wang L; Zhang Y; Wang W; Zhu Y; Chen Y; Tian B
PLoS One; 2017; 12(8):e0184110. PubMed ID: 28854261
[TBL] [Abstract][Full Text] [Related]
40. Generation of receptor-active, globotriaosyl ceramide/cholesterol lipid 'rafts' in vitro : A new assay to define factors affecting glycosphingolipid receptor activity.
Nutikka A; Lingwood C
Glycoconj J; 2004; 20(1):33-8. PubMed ID: 14973368
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
